Search results for "From ACP Journal Club"
In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER
Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/05/11/7.htm
11 May 2018
Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients
More than 20% of patients with type 2 diabetes received treatment more intensive than that recommended by HbA1c-based guidelines, a study of Medicare patients found.
https://diabetes.acponline.org/archives/2016/10/07/5.htm
7 Oct 2016
Patients surviving COVID-19 had increased risk for incident diabetes vs. persons without COVID-19
Although the effect of COVID-19 on diabetes incidence is small, according to the study, the affected population could be large, given that many at-risk people have had acute COVID-19, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/08/12/7.htm
12 Aug 2022
In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization
If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/06/08/6.htm
8 Jun 2018
Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk
An ACP Journal Club commentary noted that the mechanism by which liraglutide improves renal outcomes is uncertain and that renal benefit was driven by a decrease in the surrogate outcome of macroalbuminuria, with measures of renal impairment remaining unchanged.
https://diabetes.acponline.org/archives/2018/01/12/9.htm
12 Jan 2018
Studies show benefits of glucagon-like peptide-1 receptor agonists
A commentary reviewed the findings of REWIND, PIONEER 6, and PIONEER 4 trials, which studied the cardiovascular and glycemic control effects of dulaglutide, semaglutide, and liraglutide.
https://diabetes.acponline.org/archives/2019/10/11/7.htm
11 Oct 2019
In type 2 diabetes, a primary care–led weight management program increased weight loss and diabetes remission at 2 years
Primary care practices that want to adopt such an intervention for their patients will need a dietician or practice nurse to deliver an intensive weight loss program, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/8.htm
13 Sep 2019
In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 years
The results showed that when patients on multiple daily insulin injections received structured education, there was no additional benefit of switching to pump therapy for glycemic control, hypoglycemia rates, or quality of life, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2017/09/08/6.htm
8 Sep 2017
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin
The trial showed that an oral glucagon-like peptide-1–receptor analogue improved glycemic control compared to a dipeptidyl peptidase 4 inhibitor, but gastrointestinal side effects and cost remain barriers to use of the former class.
https://diabetes.acponline.org/archives/2019/09/13/7.htm
13 Sep 2019
Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes
While exenatide can be considered a second-line option for patients with type 2 diabetes and some may prefer its once-weekly dosing, those at high cardiovascular risk should receive agents with demonstrated cardiovascular benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/01/12/10.htm
12 Jan 2018